DWEK RAYMOND
Known title: DirectorCIK: 0001231617
Associated companies
Transaction History
| UTHR | ▲ Buy | Option Exercise | 3,000 | $526K | 4/21/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 3,000 | $857K | 4/21/2025 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 3,000 | $526K | 4/14/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 3,000 | $855K | 4/14/2025 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 4,000 | $702K | 4/7/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 4,000 | $1.1M | 4/7/2025 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 5,000 | $877K | 8/2/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 900 | $288K | 8/2/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 900 | $294K | 8/2/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 1,300 | $426K | 8/2/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 900 | $296K | 8/2/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 100 | $33K | 8/2/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 900 | $289K | 8/2/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 3,000 | $264K | 4/22/2024 | View on chart |
| UTHR | ▼ Sell | Other | 3,000 | $702K | 4/22/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 3,000 | $264K | 4/15/2024 | View on chart |
| UTHR | ▼ Sell | Other | 3,000 | $705K | 4/15/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 4,000 | $352K | 4/8/2024 | View on chart |
| UTHR | ▼ Sell | Other | 4,000 | $948K | 4/8/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 1,750 | $0 | 7/7/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,000 | $128K | 4/21/2023 | View on chart |
| UTHR | ▼ Sell | Other | 2,000 | $462K | 4/21/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,000 | $128K | 4/14/2023 | View on chart |
| UTHR | ▼ Sell | Other | 2,000 | $457K | 4/14/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 3,000 | $192K | 4/10/2023 | View on chart |
| UTHR | ▼ Sell | Other | 3,000 | $669K | 4/10/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 5,000 | $440K | 11/7/2022 | View on chart |
| UTHR | ▼ Sell | Other | 5,000 | $1.3M | 11/7/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 3,000 | $192K | 9/9/2022 | View on chart |
| UTHR | ▼ Sell | Other | 3,000 | $670K | 9/9/2022 | View on chart |
| UTHR | ▼ Sell | Open Market | 2,160 | $521K | 7/11/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,160 | $0 | 7/8/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 5,000 | $320K | 5/26/2022 | View on chart |
| UTHR | ▼ Sell | Other | 5,000 | $1.1M | 5/26/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,000 | $96K | 5/5/2022 | View on chart |
| UTHR | ▼ Sell | Other | 2,000 | $374K | 5/5/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,000 | $96K | 4/28/2022 | View on chart |
| UTHR | ▼ Sell | Other | 2,000 | $359K | 4/28/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,000 | $96K | 4/21/2022 | View on chart |
| UTHR | ▼ Sell | Other | 2,000 | $380K | 4/21/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,000 | $96K | 4/14/2022 | View on chart |
| UTHR | ▼ Sell | Other | 2,000 | $384K | 4/14/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 2,000 | $96K | 4/7/2022 | View on chart |
| UTHR | ▼ Sell | Other | 2,000 | $380K | 4/7/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 3,000 | $144K | 11/8/2021 | View on chart |
| UTHR | ▼ Sell | Other | 3,000 | $606K | 11/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
United Therapeutics Settles Litigation, Market Reassesses Valuation
United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.
United Therapeutics Settles Litigation, Market Reassesses Valuation. United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.